NLRP3 Regulates IL-4 Expression in TOX + CD4 + T Cells of Cutaneous T Cell Lymphoma to Potentially Promote Disease Progression.

In cutaneous T cell lymphoma (CTCL), a dominant Th2 profile associated with disease progression has been proposed. Moreover, although the production and regulation of IL-4 expression during the early stages of the disease may have important implications in later stages, these processes are poorly understood. Here, we demonstrate the presence of TOX ⁺ CD4 ⁺ T cells that produce IL-4 ⁺ in early-stage skin lesions of CTCL patients and reveal a complex mechanism by which the NLRP3 receptor promotes a Th2 response by controlling IL-4 production. Unassembled NLRP3 is able to translocate to the nucleus of malignant CD4 ⁺ T cells, where it binds to the human il-4 promoter. Accordingly, IL-4 expression is decreased by knocking down and increased by promoting the nuclear localization of NLRP3. We describe a positive feedback loop in which IL-4 inhibits NLRP3 inflammasome assembly, thereby further increasing its production. IL-4 induced a potentially malignant phenotype measured based on TOX expression and proliferation. This mechanism of IL-4 regulation mediated by NLRP3 is amplified in late-stage CTCL associated with disease progression. These results indicate that NLRP3 might be a key regulator of IL-4 expression in TOX ⁺ CD4 ⁺ T cells of CTCL patients and that this mechanism might have important implications in the progression of the disease.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Huanosta-Murillo, Alcántara-Hernández, Hernández-Rico, Victoria-Acosta, Miranda-Cruz, Domínguez-Gómez, Jurado-Santacruz, Patiño-López, Pérez-Koldenkova, Palma-Guzmán, Licona-Limón, Fuentes-Pananá, Lemini-López and Bonifaz.)